Scarica l'app Stockscreener
1.63
7.39%
-0.13
Pre-mercato:
1.62
-0.010
-0.61%
Precedente Chiudi:
$1.76
Aprire:
$1.72
Volume 24 ore:
154.67K
Relative Volume:
1.28
Capitalizzazione di mercato:
$19.65M
Reddito:
$52.16M
Utile/perdita netta:
$-48.60M
Rapporto P/E:
-0.3773
EPS:
-4.32
Flusso di cassa netto:
$-77.48M
1 W Prestazione:
-13.30%
1M Prestazione:
-24.88%
6M Prestazione:
-69.36%
1 anno Prestazione:
-74.54%
Intervallo 1D:
$1.5508
$1.81
Intervallo di 1 settimana:
$1.5508
$1.91
Portata 52W:
$1.5508
$10.50
Hookipa Pharma Inc Stock (HOOK) Company Profile
Nome
Hookipa Pharma Inc
Settore
Industria
Telefono
0114318906360
Indirizzo
350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY
Confronta HOOK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HOOK
Hookipa Pharma Inc
|
1.63 | 19.65M | 52.16M | -48.60M | -77.48M | -4.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Hookipa Pharma Inc Stock (HOOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-15 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-12-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-11-12 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-08 | Iniziato | Morgan Stanley | Overweight |
| 2020-11-03 | Iniziato | Truist | Buy |
| 2020-10-26 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-19 | Ripresa | H.C. Wainwright | Buy |
| 2019-09-27 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-13 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Hookipa Pharma Inc Borsa (HOOK) Ultime notizie
Hookipa Pharma stock hits 52-week low at $1.56 amid downturn - Investing.com India
Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know - MSN
BRIEF—Proposed combination of Poolbeg with HOOKIPA called off - The Pharma Letter
HOOKIPA Pharma ends talks to acquire Poolbeg Pharma By Investing.com - Investing.com Australia
Poolbeg slumps as Hookipa merger is called off - pharmaphorum
Hookipa Pharma (NASDAQ:HOOK) Shares Down 4.8% – Time to Sell? - Defense World
Poolbeg Pharma PLC (AIM:POLB) Termination of proposed combination with HOOKIPA - Share Talk
Poolbeg merger off after HOOKIPA ends discussions - Proactive Investors USA
Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger - TradingView
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”) - GlobeNewswire
HOOKIPA Pharma ends talks to acquire Poolbeg Pharma - Investing.com India
Failed Merger: Why HOOKIPA Pharma Walked Away from Poolbeg Deal - StockTitan
Hookipa Pharma stock hits 52-week low at $1.71 amid downturn - MSN
Hookipa Pharma announces enrollment completion of Phase 1b HB-500 trial - Yahoo Finance
Hookipa Pharma Files Petition to Validate Stockholder Actions at Annual Meetings - Defense World
HOOKIPA completes enrollment for HIV vaccine trial By Investing.com - Investing.com Nigeria
HOOKIPA Pharma seeks court validation for stockholder actions By Investing.com - Investing.com Australia
HOOKIPA completes enrollment for HIV vaccine trial - Investing.com India
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b - GlobeNewswire
Game-Changing HIV Vaccine Trial Fully Enrolled: HOOKIPA's Path to Potential Cure - StockTitan
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment… - Informazione.it
Poolbeg Agrees to Bid Deadline Extension for Possible Hookipa Pharma Deal - MarketWatch
Poolbeg and HOOKIPA given more time to agree merger deal - Proactive Investors UK
Poolbeg Pharma PLC (AIM:POLB) Offer Update – Extension to PUSU Deadline - Share Talk
Poolbeg Pharma granted extension to PUSU Deadline - DirectorsTalk Interviews
Poolbeg Pharma and HOOKIPA Extend Merger Deadline Amid Positive Discussions - TipRanks
HOOKIPA Pharma seeks court validation for stockholder actions - MSN
Hookipa Pharma Seeks Validation for Stockholder Meetings - TipRanks
HOOK (HOOKIPA Pharma) Shares Outstanding (EOP) : 12.05 Mil (As of Sep. 2024) - GuruFocus.com
Hookipa Pharma stock hits 52-week low at $1.73 amid market challenges - Investing.com Nigeria
Geode Capital Management LLC Cuts Stake in Hookipa Pharma Inc (NASDAQ:HOOK) - Defense World
HC Wainwright Reiterates Neutral Rating for Hookipa Pharma (NASDAQ:HOOK) - Defense World
HOOKIPA Pharma explores acquisition of Poolbeg Pharma By Investing.com - Investing.com South Africa
HOOKIPA Pharma explores acquisition of Poolbeg Pharma - Investing.com
Poolbeg Pharma notes Gilead interest in Hookipa fundraise -January 10, 2025 at 11:08 am EST - Marketscreener.com
Poolbeg Pharma PLC (AIM:POLB) Update Potential Combination of Poolbeg & HOOKIPA - Share Talk
Poolbeg Pharma update on potential combination with HOOKIPA - DirectorsTalk Interviews
Poolbeg Pharma plc ('Poolbeg”) and HOOKIPA Pharma Inc. ('HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA - The Manila Times
Poolbeg Pharma and HOOKIPA Explore Potential Merger Amid Gilead’s Interest - TipRanks
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. - GlobeNewswire
Gilead Sciences Backs HOOKIPA-Poolbeg Merger Talks with $8.7M Funding Commitment - StockTitan
HOOKIPA Pharma discloses position in takeover code filing By Investing.com - Investing.com Nigeria
Hookipa Pharma Inc Azioni (HOOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.53%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):